FDA approves EpiPen competitor Symjepi

symjepi photo

The effective but expensive EpiPen is getting some competition. The U.S. Food and Drug Administration has approved Symjepi, a prefilled syringe for the emergency treatment of allergic reactions.

Symjepi provides two single-dose syringes of epinephrine (adrenaline), which is considered the drug of choice for immediate administration in acute anaphylactic reactions to insect stings or bites, allergic reaction to foods (such as nuts), drugs and other allergens, as well as idiopathic or exercise-induced anaphylaxis.

EpiPen has been severely criticized for steadily increasing the price of its epinephrine, which can now cost more than $600 for some consumers. While marketing plans for the Symjepi were not announced, it is expected to be competitively priced.

Dr. Dennis J. Carlo, President and CEO of Adamis, said the company was preparing to submit a second application to the FDA, this one for a “junior version” of Symjepi.

“We are committed to helping patients by providing them with additional therapeutic choices,” Carlo said. “With an anticipated lower cost, small size and user-friendly design, we believe Symjepi could be an attractive option for a significant portion of both the retail (patient) and non-retail (professional) sectors of the epinephrine market.”

Carlo said the product is expected to launch in the second half of the year.

Each Symjepi prefilled syringe contains 0.3 mg epinephrine.

 

About the Author

Truman Lewis
Truman has been a bureau chief and correspondent in D.C., Los Angeles, Phoenix and elsewhere, reporting for radio, television, print and news services, for more than 30 years.